Sulfonimidamide Analogs of Oncolytic Sulfonylureas,1

John E. Toth,* Gerald B. Grindey, William J. Ehlhardt, James E. Ray, George B. Boder, Jesse R. Bewley, Kim K. Klingerman, Susan B. Gates, Sharon M. Rinzel, Richard M. Schultz, Leonard C. Weir, and John F. Worzalla
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285
J. Med. Chem., 1997, 40 (6), pp 1018–1025
DOI: 10.1021/jm960673l
Publication Date (Web): March 14, 1997
Copyright © 1997 American Chemical Society

 Dedicated to the memory of Gerry Grindey.

,
*

In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.

,

 Deceased November 16, 1993.

Abstract

A series of sulfonimidamide analogs of the oncolytic diarylsulfonylureas was synthesized and evaluated for (1) in vitro cytotoxicity against CEM cells, (2) in vivo antitumor activity against subaxillary implanted 6C3HED lymphosarcoma, and (3) metabolic breakdown to the o-sulfate of p-chloroaniline. The separated enantiomers of one sulfonimidamide analog displayed very different activities in the in vivo screening model. In general, several analogs demonstrated excellent growth inhibitory activity in the 6C3HED model when dosed orally or intraperitoneally. A correlative structure−activity relationship to the oncolytic sulfonylureas was not apparent.

Tools

History

  • Published In Issue March 14, 1997
  • Received September 26, 1996

Recommend & Share